Branmon
12-16 06:45


























P


























P





00






P

P

Ppppp












Pppp






Pp


Pppp

P

Ppppppp


Ppppp



Ppppppp

Pppppp

Pp

P


Pppp

Ppppppppppp

Ppppp

Ppppppp



Pppp

Ppppp

Pp

Ppppppp

Pp

Pppppppppp

Pp

Pppp


Ppppp

Pppp

Ppp

Pppp

Pppppp

Pppppp

P

P

Ppp

P



Ppp

Ppppppp




P

Pp

Pp

Pppppppp



P


P

Ppp

P



P


Pp

P

P

P


Ppppp


Ppp

Pp







Ppp

P

P


Pp

P


Pppp

P

P




P

P



Pppp



P






P

P

P



P




Pp


Pp



P


P


Pp


P

P




P




Pp


P


P

Pp


P












P


P

Pp

P


P

Tilray Stock Surges 24% Amid Trump Administration's Cannabis Rescheduling Plans and New Product Launch
Tilray Inc. stock soared over 24% in pre-market trading driven by two main factors: the Trump administration's plan to reclassify marijuana as a less dangerous drug, signaling a major policy shift, and Tilray's launch of a new vape product. This anticipated reclassification is expected to reduce industry tax burdens, ease banking restrictions, and boost medical research, positively impacting the cannabis sector. Other cannabis stocks like Canopy Growth and SNDL also saw significant gains, reflecting broad market optimism.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment